The preclinical development of human-specific immunotherapeutics is currently hampered by a lack of in vivo immunotherapy models for efficacy testing that feature human targets in the presence of a functional immune system. There's also a need to study unique immune-related adverse events (irAEs), caused by I/O agents potentiating tumor-reactive immune responses, leading to on/off target non-specific immune attack.
In this webinar, Dr Hongjuan Zhang explores novel HuGEMM™ and HuCELL™ platforms for assessing human-specific immunotherapies. These models feature humanized drug targets replacing their murine counterpart on host T cells or tumor cells and within a fully functional murine immune system. Hongjuan also presents the latest research applying these platforms to assessing immune related toxicities, to accelerate immuno-oncology drug discovery programs.
Hongjuan Zhang, PhD, Senior Scientist, Cancer Biology and Immunology focuses on in vitro and in vivo immuno-oncology assay development. Dr Zhang received her PhD from the School of Life Science at Tsinghua University, Beijing. She performed her postdoctoral training at the National Institute of Biological Science (NIBS, Beijing), where she studied the tumorigenesis of lung cancer using genetically engineered mouse models. Hongjuan also trained as a postdoctoral research fellow in the Department of Surgery, University of Michigan, studying the role epigenetic modifiers in regulating T cell activation in the context of tumor immunology.